Inolex v. Actera Ingredients: Cosmetic Preservative Patent Battle Ends in Prejudicial Dismissal
Inolex, Inc. and Inolex Investment Corp. brought a patent infringement action against Actera Ingredients, Inc. in Delaware over two patents protecting caprylhydroxamic acid-based preservative blends used in personal care formulations. After 532 days of litigation, both parties agreed to dismiss all claims with prejudice — and with no award of costs or attorneys’ fees to either side.
Inolex and Actera Reach Stipulated End to Preservative IP Dispute
On April 11, 2024, Inolex, Inc. and Inolex Investment Corp. filed suit against Actera Ingredients, Inc. in the U.S. District Court for the District of Delaware before Judge Colm F. Connolly. The complaint alleged infringement of two U.S. patents — US11291204B2 and US10897899B2 — covering caprylhydroxamic acid-based cosmetic preservative compositions. The accused products included Actera’s Spectrastat and TeraStat product lines, formulated with varying concentrations of caprylhydroxamic acid, caprylyl glycol, propanediol, and related glyceryl ether compounds.
The case closed on September 25, 2025, when the parties jointly filed a stipulation of dismissal under Federal Rule of Civil Procedure 41(a)(1)(A)(ii). All claims and affirmative defenses were dismissed with prejudice, with each party bearing its own legal costs and attorneys’ fees. The court retained jurisdiction to enforce any future disputes relating to the subject matter — a clause that typically signals an underlying settlement agreement governing ongoing commercial or licensing terms.
At 532 days, the case ran longer than many stipulated dismissals, suggesting the parties engaged in meaningful discovery or licensing negotiations before reaching resolution. The with-prejudice nature of the dismissal is commercially significant: Inolex cannot revive these specific infringement claims against Actera in a future action. The public record does not disclose the terms of any underlying agreement, leaving the nature of any commercial settlement or licensing arrangement unknown.
Filing to Dismissed with Prejudice in 532 days
532 days — above the median for settled Delaware patent cases, suggesting substantive pre-trial engagement
Dismissed with prejudice: what the stipulation means for both parties
Rule 41(a)(1)(A)(ii) dismissal with prejudice explained
A stipulated dismissal under Rule 41(a)(1)(A)(ii) requires agreement from all parties who have appeared. When entered ‘with prejudice,’ the dismissal operates as a final adjudication on the merits — Inolex is permanently barred from asserting the same claims against Actera under US11291204B2 and US10897899B2 in any future action. The court’s retained jurisdiction clause further suggests an enforceable underlying agreement exists between the parties.
Permanent bar on re-filingInolex trades litigation rights for certainty — likely a negotiated resolution
By agreeing to a with-prejudice dismissal, Inolex surrenders the right to re-assert these two patents against Actera’s Spectrastat and TeraStat lines. This is consistent with a negotiated outcome — whether a licensing arrangement, market boundary agreement, or product reformulation commitment — rather than an outright loss. The no-costs clause suggests neither party conceded defeat.
Claims extinguished against ActeraActera secures closure — but patent risk across the sector persists
Actera obtains certainty that Inolex cannot re-litigate these specific patent claims. However, the with-prejudice dismissal does not invalidate US11291204B2 or US10897899B2 — the patents remain in force and enforceable against other market participants. Actera’s Spectrastat product line may remain subject to any terms agreed privately, and third-party infringement exposure from other Inolex portfolio patents cannot be ruled out.
No invalidity ruling obtainedActive patents — sector-wide enforcement risk remains live
Neither Inolex patent was invalidated or narrowed through this proceeding. Competing formulators working with caprylhydroxamic acid, caprylyl glycol, propanediol, or caprylyl glyceryl ether-based preservative blends should treat US11291204B2 and US10897899B2 as active enforcement risks. The outcome signals Inolex is willing to litigate — and potentially to license — rather than tolerate perceived infringement in the natural cosmetic preservative space.
Patents remain enforceableFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Inolex, Inc. | Company | Cosmetic ingredient innovator — holder of US11291204B2 and US10897899B2Search in Eureka ↗ |
| Co-Plaintiff | Inolex Investment, Corp. | Company | Search in Eureka ↗ |
| Defendant | Actera Ingredients, Inc. | Company | Cosmetic preservative ingredient supplier — maker of the Spectrastat and TeraStat product linesSearch in Eureka ↗ |
| Plaintiff counsel | Anna Pedraza | Attorney | Counsel for Inolex, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Geng Hua | Attorney | Counsel for Inolex, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Kaan Ekiner | Attorney | Counsel for Inolex, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Keri L. Schaubert | Attorney | Counsel for Inolex, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Madison H. McNulty | Attorney | Counsel for Inolex, Inc.Search in Eureka ↗ |
| Plaintiff counsel | W. Blake Coblentz | Attorney | Counsel for Inolex, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Cozen O’connor PC | Law Firm | Representing Inolex, Inc.Search in Eureka ↗ |
| Defendant counsel | Austin C. Diehl | Attorney | Counsel for Actera Ingredients, Inc.Search in Eureka ↗ |
| Defendant counsel | Stephanie S. Riley | Attorney | Counsel for Actera Ingredients, Inc.Search in Eureka ↗ |
| Defendant counsel | Zachary Thomas Grieb Murphy | Attorney | Counsel for Actera Ingredients, Inc.Search in Eureka ↗ |
| Defendant law firm | Womble Bond Dickinson (US) LLP | Law Firm | Representing Actera Ingredients, Inc.Search in Eureka ↗ |
| Presiding judge | Judge Colm F. Connolly | Judge | Delaware District CourtSearch in Eureka ↗ |
Official order — verbatim text
The stipulation is carefully drafted to foreclose future litigation between these specific parties: the with-prejudice language extinguishes all claims and affirmative defenses — including any invalidity counterclaims Actera may have asserted. Critically, the equal no-costs provision avoids any inference of a prevailing party, which would typically trigger fee-shifting analysis under 35 U.S.C. § 285. The retained jurisdiction clause is the key signal that a separate, enforceable agreement governs the parties’ ongoing relationship.
US11291204B2 & US10897899B2 — Caprylhydroxamic Acid Cosmetic Preservative Blends
US11291204B2, filed via application US16/781636, and US10897899B2, filed via application US16/918648, both protect compositions and methods relating to caprylhydroxamic acid-based blends used as preservatives and antimicrobial agents in cosmetic and personal care formulations. The patents cover specific weight-percentage ranges of active ingredients — including caprylhydroxamic acid, caprylyl glycol, 1,3-propanediol, caprylyl glyceryl ether, and related compounds — that together deliver preservation efficacy meeting regulatory and consumer safety standards without traditional synthetic preservatives.
These patents sit at the commercial intersection of two major trends: the clean beauty movement driving demand for paraben-free, synthetic-preservative-free formulations, and the technical challenge of achieving broad-spectrum antimicrobial activity with naturally-derived ingredients. Inolex’s Spectrastat-branded ingredient portfolio — and Actera’s competing Spectrastat and TeraStat lines — compete directly in this high-growth segment. Any formulator developing multifunctional preservative blends incorporating these chemical classes should treat the Inolex portfolio as a primary FTO priority.
Should your team run an FTO against US11291204B2 and US10897899B2?
If your R&D or product team is developing preservative systems based on caprylhydroxamic acid, caprylyl glycol, caprylyl glyceryl ether, 1,3-propanediol, or glyceryl caprylate blends — or if you are sourcing multifunctional preservative ingredients from any supplier in this space — an FTO analysis against the Inolex patent family is advisable before commercialisation. The specific weight-percentage claim ranges in these patents mean that formulation-level detail, not just ingredient identity, determines infringement exposure.
PatSnap Eureka’s FTO Search Agent can map the full Inolex patent family, identify claim scope across continuation and related applications, and flag overlapping prior art or design-around opportunities. For ingredient suppliers and finished-goods formulators alike, early-stage FTO analysis against these active patents is significantly less costly than responding to a Delaware infringement action — as Actera’s 532-day litigation experience illustrates.
Run a freedom-to-operate analysis on US11291204B2 to assess your product’s exposure
Run FTO in Eureka →Similar Patent Disputes in Cosmetic Ingredient and Preservative Technology
Cases involving caprylhydroxamic acid, multifunctional preservative patents, and cosmetic ingredient infringement actions in Delaware and related federal courts.
What this case signals for the cosmetic preservative IP landscape
Inolex’s willingness to litigate in Delaware over preservative blends raises the stakes for every competing formulator in the natural personal care sector.
Both patents survive — enforcement risk is real for the broader market
US11291204B2 and US10897899B2 emerged from this dispute intact and enforceable. Any company formulating with caprylhydroxamic acid, caprylyl glycol, or related propanediol-based preservative blends should conduct a Freedom-to-Operate analysis before product launch or market expansion. The case demonstrates Inolex monitors the competitive landscape actively.
Retained jurisdiction clause signals a private deal — watch for licensing activity
The court’s retained jurisdiction provision is a standard indicator that the parties executed a confidential settlement or licensing agreement alongside the dismissal. Competitors should monitor Actera’s product line for any reformulation or labelling changes post-settlement, as these may reflect the contours of any privately agreed terms.
Inolex v Actera — key questions answered
Inolex asserted two patents: US11291204B2 (application US16/781636) and US10897899B2 (application US16/918648). Both cover caprylhydroxamic acid-based cosmetic preservative compositions at specific weight-percentage ranges, including blends with caprylyl glycol, 1,3-propanediol, caprylyl glyceryl ether, and related compounds.
A dismissal with prejudice operates as a final judgment on the merits. Inolex is permanently barred from reasserting the same patent claims — under US11291204B2 and US10897899B2 — against Actera’s Spectrastat and TeraStat products. The patents themselves, however, remain valid and enforceable against other third parties.
No. The case closed via a stipulated dismissal under Rule 41(a)(1)(A)(ii) — a consensual procedural termination agreed to by both parties. No court issued a merits ruling, claim construction order, or invalidity finding. US11291204B2 and US10897899B2 remain granted and enforceable as of the case closure date.
The retained jurisdiction clause in the dismissal stipulation is a standard indicator that the parties executed a separate, confidential settlement or licensing agreement. Courts retain jurisdiction in these circumstances to adjudicate any future breach or enforcement disputes arising from that private agreement, without requiring the parties to file a new lawsuit.
The accused Actera products included the Spectrastat CGE Natural MB, Spectrastat G2 Natural MB, Spectrastat OEL, Spectrastat OL, Spectrastat PHL product lines, and the TeraStat N product. These are multifunctional cosmetic preservative blends incorporating various combinations of caprylhydroxamic acid, caprylyl glycol, propanediol, caprylyl glyceryl ether, and related ingredients.
PatSnap Eureka searches patents and litigation data to answer instantly.